Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Mar 14;51(2):401-421.
doi: 10.1093/schbul/sbae051.

Measuring Cognitive Impairments Associated With Schizophrenia in Clinical Practice: Overview of Current Challenges and Future Opportunities

Affiliations
Review

Measuring Cognitive Impairments Associated With Schizophrenia in Clinical Practice: Overview of Current Challenges and Future Opportunities

Keith H Nuechterlein et al. Schizophr Bull. .

Abstract

Background: Cognitive impairment associated with schizophrenia (CIAS) negatively impacts daily functioning, quality of life, and recovery, yet effective pharmacotherapies and practical assessments for clinical practice are lacking. Despite the pivotal progress made with establishment of the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) for clinical research, implementation of the full MCCB is too time-consuming and cost-ineffective for most clinicians in clinical practice.

Study design: Here we discuss current assessments in relation to delivery format (interview-based and performance-based), validity, ease of use for clinicians and patients, reliability/reproducibility, cost-effectiveness, and suitability for clinical implementation. Key challenges and future opportunities for improving cognitive assessments are also presented.

Study results: Current assessments that require 30 min to complete would have value in clinical settings, but the associated staff training and time required might preclude their application in most clinical settings. Initial profiling of cognitive deficits may require about 30 min to assist in the selection of evidence-based treatments; follow-up monitoring with brief assessments (10-15 min in duration) to detect treatment-related effects on global cognition may complement this approach. Guidance on validated brief cognitive tests for the strategic monitoring of treatment effects on CIAS is necessary.

Conclusions: With increased advancements in technology-based and remote assessments, development of validated formats of remote and in-person assessment, and the necessary training models and infrastructure required for implementation, are likely to be of increasing clinical relevance for future clinical practice.

Keywords: brief cognitive assessment; clinician training; cost-effective cognitive assessment; interview-based assessment; performance-based assessment.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
A diagram summarizing proposed next steps for the optimization and delivery of improved cognitive assessment in clinical settings. Note: CIAS, cognitive impairment in schizophrenia.

References

    1. Keefe RSE. Why are there no approved treatments for cognitive impairment in schizophrenia? World Psychiatry. 2019;18(2):167–168. - PMC - PubMed
    1. Nutt D, Gispen-de Wied CC, Arango C, et al. Cognition in schizophrenia: summary Nice Consultation Meeting 2012. Eur Neuropsychopharmacol. 2013;23(8):769–778. - PubMed
    1. Zhu Y, Womer FY, Leng H, et al. The relationship between cognitive dysfunction and symptom dimensions across schizophrenia, bipolar disorder, and major depressive disorder. Front Psychiatry. 2019;10:253. - PMC - PubMed
    1. Jak AJ, Crocker LD, Aupperle RL, Clausen A, Bomyea J.. Neurocognition in PTSD: treatment insights and implications. Curr Top Behav Neurosci. 2018;38:93–116. - PubMed
    1. Gotra MY, Hill SK, Gershon ES, et al. Distinguishing patterns of impairment on inhibitory control and general cognitive ability among bipolar with and without psychosis, schizophrenia, and schizoaffective disorder. Schizophr Res. 2020;223:148–157. - PMC - PubMed

MeSH terms